These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 2867292

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
    Labrie F, Dupont A, Giguère M, Borsanyi JP, Lacourciere Y, Bélanger A, Lachance R, Emond J, Monfette G.
    Prog Clin Biol Res; 1988; 260():41-62. PubMed ID: 3283766
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Benefits of combination therapy with flutamide in patients relapsing after castration.
    Labrie F, Dupont A, Giguere M, Borsanyi JP, Lacourciere Y, Monfette G, Emond J, Bergeron N.
    Br J Urol; 1988 Apr; 61(4):341-6. PubMed ID: 3289676
    [Abstract] [Full Text] [Related]

  • 5. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients.
    Labrie F, Dupont A, Giguere M, Borsanyi JP, Lacourciere Y, Belanger A, Lachance R, Emond J, Monfette G.
    J Steroid Biochem; 1987 Apr; 27(1-3):525-32. PubMed ID: 2961937
    [Abstract] [Full Text] [Related]

  • 6. Effect of surgical and biochemical castration and an antiandrogen on patients with stage D2 prostatic cancer: preliminary results.
    Givner ML, Millard OH.
    Prog Clin Biol Res; 1987 Apr; 243A():439-43. PubMed ID: 2958865
    [No Abstract] [Full Text] [Related]

  • 7. Serum luteinizing hormone (LH) biological activity in castrated patients with cancer of the prostate receiving a pure antiandrogen and in estrogen-pretreated patients treated with an LH-releasing hormone agonist and antiandrogen.
    St Arnaud R, Lachance R, Dupont A, Labrie F.
    J Clin Endocrinol Metab; 1986 Aug; 63(2):297-302. PubMed ID: 3522618
    [Abstract] [Full Text] [Related]

  • 8. Changes in plasma lipoproteins during various androgen suppression therapies in men with prostatic carcinoma: effects of orchiectomy, estrogen, and combination treatment with luteinizing hormone-releasing hormone agonist and flutamide.
    Moorjani S, Dupont A, Labrie F, Lupien PJ, Gagné C, Brun D, Giguère M, Bélanger A, Cusan L.
    J Clin Endocrinol Metab; 1988 Feb; 66(2):314-22. PubMed ID: 3276721
    [Abstract] [Full Text] [Related]

  • 9. Re Benefits of combination therapy with flutamide in patients relapsing after castration.
    Br J Urol; 1988 Nov; 62(5):495-6. PubMed ID: 3208035
    [No Abstract] [Full Text] [Related]

  • 10. Combination therapy with flutamide and castration: its benefits at various stages of prostate cancer.
    Labrie F, Dupont A, Cusan L, Manhès G, Bergeron N, Lacourcière Y, Pineault S, Bélanger A, Monfette G, Emond J.
    Prog Clin Biol Res; 1989 Nov; 303():161-7. PubMed ID: 2674982
    [No Abstract] [Full Text] [Related]

  • 11. [LHRH agonists combined with antiandrogens in the treatment of metastasizing prostatic carcinoma].
    Senn E, Müller J, Alioth H.
    Schweiz Rundsch Med Prax; 1985 Nov 26; 74(48):1340-4. PubMed ID: 3003863
    [No Abstract] [Full Text] [Related]

  • 12. Effect of adrenalectomy, flutamide, and leuprolide on the growth of the Dunning rat R-3327 prostatic carcinoma.
    Kung TT, Mingo GG, Siegel MI, Watnick AS.
    Prostate; 1988 Nov 26; 12(4):357-63. PubMed ID: 3134647
    [Abstract] [Full Text] [Related]

  • 13. [Complete androgen blockade (orchiectomy + flutamide) versus androgen blockade with cytostasis (orchiectomy + estramustine) in the treatment of virginal advanced prostate cancer].
    Flamm J, Fischer M.
    Wien Klin Wochenschr; 1988 Sep 09; 100(17):589-92. PubMed ID: 3055689
    [Abstract] [Full Text] [Related]

  • 14. Relative effectiveness of alternative androgen withdrawal therapies in initiating regression of rat prostate.
    Rennie PS, Bruchovsky N, Goldenberg SL, Lawson D, Fletcher T, Foekens JA.
    J Urol; 1988 Jun 09; 139(6):1337-42. PubMed ID: 2967378
    [Abstract] [Full Text] [Related]

  • 15. Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival.
    Labrie F, Dupont A, Belanger A, Giguere M, Lacoursiere Y, Emond J, Monfette G, Bergeron V.
    J Steroid Biochem; 1985 Nov 09; 23(5B):833-41. PubMed ID: 2934579
    [Abstract] [Full Text] [Related]

  • 16. Antiandrogenic drugs.
    McLeod DG.
    Cancer; 1993 Feb 01; 71(3 Suppl):1046-9. PubMed ID: 8428326
    [Abstract] [Full Text] [Related]

  • 17. [Antiandrogens in monotherapy or combined therapy for treatment of advanced cancer of the prostate].
    Pavone-Macaluso M, Serretta V, Pavone C, Romano C, Daricello G.
    Arch Esp Urol; 1989 Feb 01; 42 Suppl 2():197-205. PubMed ID: 2534783
    [Abstract] [Full Text] [Related]

  • 18. Stimulation of the circulating levels of glycoprotein hormone alpha-subunit after combined administration of a luteinizing hormone-releasing hormone (LHRH) agonist and flutamide in patients with cancer of the prostate.
    St-Arnaud R, Lachance R, Dupont A, Labrie F.
    Clin Invest Med; 1986 Nov 01; 9(4):215-21. PubMed ID: 2433088
    [Abstract] [Full Text] [Related]

  • 19. Advanced prostatic cancer: clinical and hormonal response to flutamide in patients pretreated with LHRH analogue and cyproterone acetate.
    Di Silverio F, Sciarra F, D'Eramo G.
    Eur Urol; 1990 Nov 01; 18(1):10-5. PubMed ID: 2144819
    [Abstract] [Full Text] [Related]

  • 20. Treatment of prostatic cancer. Newer forms of androgen deprivation.
    Soloway MS.
    Postgrad Med; 1986 Jul 01; 80(1):249-52, 257-8. PubMed ID: 2941729
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.